OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HSTI.PK55

High Sierra Technologies Inc

Drug RetailersVerified

High Sierra Technologies Inc has a negative equity position of -$436,270 million, indicating a significant financial distress with total liabilities of $584,670 million and total assets of $148,410 million. The company's liquidity is further strained by a current ratio of 0.12, suggesting a high risk of short-term insolvency. The negative operating cash flow of -$176,520 million and free cash flow of -$25,700 million indicate a lack of cash generation from operations. The company's profitability is severely negative, with a net income of -$34,540 million and an operating income of -$19,020 million. The return on equity of 7.92% is misleading due to the negative equity base, and the return on assets of -23.27% indicates a poor use of assets to generate profit. These metrics are far below the industry medians for profitability and returns, suggesting a significant underperformance relative to peers. The company's revenue is reported as $0 million, indicating a lack of disclosed revenue streams or operational activity. There is no information provided on geographic exposure or segment performance, making it difficult to assess revenue concentration or diversification. The company's growth trajectory is unclear due to the absence of revenue data and the negative financial performance. The outlook for the current and next fiscal years is not provided, but the negative operating and net income suggest a challenging environment for growth. The company faces significant liquidity and solvency risks, with a negative net cash position after subtracting total debt. The dilution risk is currently low, but the negative equity and high debt levels could lead to future dilution if the company requires additional capital. The adjustments applied in the valuation reflect the company's financial distress and the potential for further dilution. There are no recent events or filings provided that would indicate significant changes in the company's operations or financial status. The lack of disclosed revenue and the negative financial performance suggest a need for further investigation into the company's business model and financial health.

30-day price · HSTI.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyHigh Sierra Technologies Inc
TickerHSTI.PK
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. High Sierra Technologies Inc operates in the drug retailing industry, providing pharmaceutical and consumer health products to customers.

Classification. The company is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry with a confidence level of 0.92.

High Sierra Technologies Inc has a negative equity position of -$436,270 million, indicating a significant financial distress with total liabilities of $584,670 million and total assets of $148,410 million. The company's liquidity is further strained by a current ratio of 0.12, suggesting a high risk of short-term insolvency. The negative operating cash flow of -$176,520 million and free cash flow of -$25,700 million indicate a lack of cash generation from operations. The company's profitability is severely negative, with a net income of -$34,540 million and an operating income of -$19,020 million. The return on equity of 7.92% is misleading due to the negative equity base, and the return on assets of -23.27% indicates a poor use of assets to generate profit. These metrics are far below the industry medians for profitability and returns, suggesting a significant underperformance relative to peers. The company's revenue is reported as $0 million, indicating a lack of disclosed revenue streams or operational activity. There is no information provided on geographic exposure or segment performance, making it difficult to assess revenue concentration or diversification. The company's growth trajectory is unclear due to the absence of revenue data and the negative financial performance. The outlook for the current and next fiscal years is not provided, but the negative operating and net income suggest a challenging environment for growth. The company faces significant liquidity and solvency risks, with a negative net cash position after subtracting total debt. The dilution risk is currently low, but the negative equity and high debt levels could lead to future dilution if the company requires additional capital. The adjustments applied in the valuation reflect the company's financial distress and the potential for further dilution. There are no recent events or filings provided that would indicate significant changes in the company's operations or financial status. The lack of disclosed revenue and the negative financial performance suggest a need for further investigation into the company's business model and financial health.
Key takeaways
  • High Sierra Technologies Inc is in a severe financial distress with negative equity and high liabilities.
  • The company's profitability is extremely poor, with significant negative net and operating income.
  • There is no disclosed revenue, indicating a lack of operational activity or financial transparency.
  • The company's liquidity and solvency risks are high, with a negative net cash position and a low current ratio.
  • The outlook for growth is uncertain due to the absence of revenue data and negative financial performance.
  • The company's risk profile is dominated by liquidity and solvency concerns, with potential for future dilution.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$0.00
Gross profit
Operating income-$19.0k
Net income-$34.5k
R&D
SG&A
D&A
SBC
Operating cash flow-$176.5k
CapEx
Free cash flow-$25.7k
Total assets$148.4k
Total liabilities$584.7k
Total equity-$436.3k
Cash & equivalents
Long-term debt$488.8k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$0.00-$42.5k-$42.5k
FY-3$0.00-$462.6k-$476.2k-$637.3k
FY-2$0.00-$257.9k-$305.5k-$270.2k
FY-1$0.00-$255.9k-$316.4k-$281.1k
FY0$0.00-$238.4k-$323.9k-$311.0k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$220.2k$194.8k
FY-3$166.2k-$281.4k
FY-2$167.5k-$352.4k
FY-1$148.4k-$436.3k
FY0$101.5k-$510.3k
PeriodOCFCapExFCFSBC
FY-4-$10.3k
FY-3-$422.9k-$176.8k-$637.3k
FY-2-$187.7k$0.00-$270.2k
FY-1-$176.5k-$281.1k
FY0-$219.7k-$43.4k-$311.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$19.0k-$34.5k-$25.7k
FQ-6$0.00-$97.9k-$114.0k-$123.9k
FQ-5$0.00-$34.6k-$51.9k-$67.8k
FQ-4$0.00-$34.9k-$52.4k-$42.0k
FQ-3$0.00-$71.0k-$105.6k-$77.3k
FQ-2$0.00-$75.2k-$95.0k-$84.0k
FQ-1$0.00-$77.1k-$96.0k-$86.8k
FQ0$0.00-$73.2k-$94.5k-$84.3k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$148.4k-$436.3k
FQ-6$196.4k-$500.3k
FQ-5$132.5k-$552.2k
FQ-4$109.2k-$604.6k
FQ-3$101.5k-$510.3k
FQ-2$81.9k-$602.0k
FQ-1$59.0k-$673.0k
FQ0$65.8k-$757.7k
PeriodOCFCapExFCFSBC
FQ-7-$176.5k-$25.7k
FQ-6-$93.2k-$18.7k-$123.9k
FQ-5-$146.8k-$43.4k-$67.8k
FQ-4-$159.6k-$43.4k-$42.0k
FQ-3-$219.7k-$43.4k-$77.3k
FQ-2-$14.7k$0.00-$84.0k
FQ-1-$46.4k$0.00-$86.8k
FQ0-$119.4k$0.00-$84.3k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$436.3k
Net cash-$488.8k
Current ratio0.1
Debt/Equity-1.1
ROA-23.3%
ROE7.9%
Cash conversion5.1%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricHSTI.PKActivity
Op margin3.1% medp25 1.2% · p75 6.8%
Net margin2.0% medp25 0.7% · p75 4.1%
Gross margin26.1% medp25 17.2% · p75 32.0%
CapEx / revenue-2.5% medp25 -4.6% · p75 -1.4%
Debt / equity-112.0%56.0% medp25 16.8% · p75 121.1%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 05:22 UTC#8c7cae6a
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 03:52 UTCJob: 5f989c0d